InvestorsHub on MSN

TransCode Therapeutics shares surge 50% after acquiring Polynoma and securing $25 million financing

TransCode Therapeutics (NASDAQ:RNAZ) shares jumped 50% on Wednesday after the company announced the acquisition of Polynoma ...
TipRanks on MSN

TransCode Therapeutics Completes Phase 1a Trial for TTX-MC138

TransCode Therapeutics ( ($RNAZ) ) has issued an update. On October 14, 2025, TransCode Therapeutics announced the completion of its Phase 1a ...
KXAN

An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split if Necessary

We have been fortunate to complete two financings in recent months. We believe that these two financings together have provided enough capital to support TTX-MC138's Phase I clinical trial and company ...
Nasdaq

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported ...
Morningstar

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode’s RIG-I agonist precursor comprises single-stranded 5’-uncapped biphosphate or triphosphate oligonucleotides having a sequence complementary to an endogenous microRNA. The precursor may be ...
Benzinga.com

Why Transcode Therapeutics (RNAZ) Stock Is Down 60%

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. Our government trade tracker caught Pelosi’s 169% AI winner.
Business Insider

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, ...